# Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.

> **NCT05751252** · EARLY_PHASE1 · COMPLETED · sponsor: **University Hospital, Lille** · enrollment: 20 (actual)

## Conditions studied

- Polycystic Ovary Syndrome

## Interventions

- **DRUG:** Ganirelix
- **DRUG:** Ganirelix

## Key facts

- **NCT ID:** NCT05751252
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-17
- **Primary completion:** 2025-02-09
- **Final completion:** 2025-02-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751252, "Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05751252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*